Alexion Pharmaceuticals, Inc. (ALXN)
| Market Cap | 33.10B |
| Revenue (ttm) | 6.07B |
| Net Income (ttm) | 603.40M |
| Shares Out | 220.10M |
| EPS (ttm) | 2.72 |
| PE Ratio | 55.17 |
| Forward PE | 12.02 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | March 8 |
| Last Price | $150.06 |
| Previous Close | $150.10 |
| Change ($) | -0.04 |
| Change (%) | -0.03% |
| Day's Open | 149.21 |
| Day's Range | 149.17 - 151.11 |
| Day's Volume | 3,197,547 |
| 52-Week Range | 72.67 - 162.60 |
Alexion (ALXN) reported earnings 30 days ago. What's next for the stock?
BOSTON--(BUSINESS WIRE)--Alexion announces upcoming data presentations at the 73rd annual meeting of the American Academy of Neurology.
NEW YORK, Feb. 26, 2021 /PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your...
The Nasdaq dropped 3.52% on Feb 25 for its worst session since October on rising rate worries. However, some stocks still remained in the green on that day or lost little.
SAN DIEGO--(BUSINESS WIRE)---- $ALXN #Alexionpharmaceuticals--Arcturus Therapeutics Acquires Exclusive License to mRNA Manufacturing Technology from Alexion Pharmaceuticals
Paulson & Co., the firm led by John Paulson (Trades, Portfolio), disclosed this week that its top five buys during the fourth quarter of 2020 were in Horizon Therapeutics PLC (NASDAQ:HZNP), Ba...
Value investing is essentially about selecting stocks that are usually cheap but fundamentally sound. Sanmina Corporation (SANM), Canadian Solar (CSIQ), Celestica (CLS) and Alexion Pharmaceuti...
Here are five of the 61 value stocks with discounted PEG.
Top Ranked Growth Stocks to Buy for February 10th
Let's take a look at some ETFs with exposure to major players in the U.S. biotech industry post their fourth-quarter earnings releases amid the coronavirus crisis.
Alexion Pharmaceuticals (ALXN) beats earnings and sales estimates for the fourth quarter of 2020.
Alexion (ALXN) delivered earnings and revenue surprises of 18.40% and 5.70%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
BOSTON--(BUSINESS WIRE)--Alexion Reports Fourth Quarter and Full Year 2020 Results
Alexion (ALXN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
These top-ranked stocks are likely to beat on bottom line in their next releases.
Alexion (ALXN) is set to provide updates on revenues and earnings when it releases fourth-quarter 2020 results on Feb 4.
P/B ratio is emerging as a convenient tool to identify low-priced stocks that have high growth prospects.
Earnings season is in full swing, and we have put together a preview of some of the world's largest players in the health care sector reporting this coming week.
You can still find deeply discounted stocks if you do a little digging.
Value investing is essentially about selecting stocks that are usually cheap but fundamentally sound. Canadian Solar (CSIQ), Alexion Pharmaceuticals (ALXN), Vale S.A.
Alexion (ALXN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BOSTON--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that the Company will report its financial results for the fourth quarter and full year ended December 31,...
Here are five picks out of 45 top-ranked stocks with discounted PEG.
Alexion (ALXN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
NEW YORK, Jan. 14, 2021 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN)...
Alexion (ALXN) decides to stop further enrollment in the late-stage study of Ultomiris in adults with severe COVID-19 requiring mechanical ventilation due to lack of efficacy.
P/B ratio is emerging as a convenient tool to identify low-priced stocks that have high growth prospects.
Alexion Pharmaceuticals Inc. ALXN said late Wednesday it stopped enrolling patients in a clinical study testing a treatment for severe COVID-19 patients based on the recommendation of a data m...
BOSTON--(BUSINESS WIRE)--Alexion Highlights Commercial, Clinical and Financial Progress at the 39th Annual J.P. Morgan Healthcare Conference
BOSTON--(BUSINESS WIRE)--Alexion to Present at the 39th Annual J.P. Morgan Healthcare Conference
NEW YORK, Jan. 5, 2021 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) ...
NEW YORK, Dec. 24, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN)...
Here's how three nascent drugmakers could make 2021 a banner year for your portfolio.
These stocks have been struggling of late. Now could be a great time to scoop them up.
NEW YORK, Dec. 18, 2020 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in Ne...
NEW YORK, Dec. 16, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN)...
Here's why AstraZeneca's shareholders can expect healthy returns from this $39 billion investment.
NEW YORK, Dec. 15, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of Al...
Seeking Alpha Transcripts | Healthcare AstraZeneca PLC (AZN) AstraZeneca to acquire Alexion Conference Call (Transcript) Dec. 15, 2020 9:50 AM ET | | About: AstraZeneca PLC (AZN), AZNCF by: SA...
WILMINGTON, Del., Dec. 14, 2020 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A. announces that it is investigating Alexion Pharmaceuticals, Inc. (“Alexion”) (NASDAQ GS: ALXN) regarding possible bre...
NEW YORK, Dec. 14, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Alexion Pharmaceuticals, Inc....
The Nasdaq Composite looked to get back into record territory on Monday.
Alexion (ALXN) is set to be acquired by AstraZeneca for $39 billion or $175 per share. The acquisition is expected to close in the third quarter of 2021.
Over the weekend, AstraZeneca made a $39 billion offer to acquire Alexion Pharmaceuticals in a deal that looks like it will benefit both parties.
Alexion Pharmaceuticals Inc. (NASDAQ: ALXN) shares shot up on Monday after it was announced over the weekend that the company would be acquired by AstraZeneca PLC (NASDAQ: AZN).
About ALXN
Alexion Pharmaceuticals develops and commercializes various therapeutic products. The company offers ULTOMIRIS for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). It also provides Strensiq for patients with hypophosphatasia; Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency; and Andexxa, a reversal agent for patien... [Read more...]
| Industry Biotechnology | IPO Date Feb 28, 1996 |
| CEO Ludwig Hantson | Employees 3,837 |
| Stock Exchange NASDAQ | Ticker Symbol ALXN |
Financial Performance
In 2020, ALXN's revenue was $6.07 billion, an increase of 21.61% compared to the previous year's $4.99 billion. Earnings were $603.40 million, a decrease of -74.90%.
Analyst Forecasts
According to 18 analysts, the average rating for ALXN stock is "Hold." The 12-month stock price forecast is 172.65, which is an increase of 15.05% from the latest price.